Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 3/20 | 0.62 |
| ▸ | ACHE | P22303 | 3/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.58 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indoramin SCHEMBL49517 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Indoramin SCHEMBL123678 | 0.99 | ADRA1D (0.98) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Indoramin SCHEMBL29801648 | 0.99 | ADRA1D (0.98) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Indoramin SCHEMBL1651262 | 0.98 | ADRA1D (0.96) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11303310 | 0.92 | ADRA2A (0.85) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11506582 | 0.92 | ADRA2A (0.85) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11545710 | 0.91 | ADRA2A (0.83) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL11545694 | 0.91 | ADRA2A (0.83) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11070428 | 0.90 | ADRA2A (0.81) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL10783732 | 0.89 | ADRA2A (0.80) | ADRA1DADRA1AADRA1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4403176-A2 | TOPICAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ANAL FISSURES AND HEMORRHOIDS | Ferring B.V. (NL) | 2024-07-24 | — | — | EP | claimed |
| US-20240165089-A1 | METHOD FOR TREATING MYOPIA WITH VINPOCETINE | Eye Hospital, Wenzhou Medical University (CN) | 2024-05-23 | — | — | US | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| CN-115003278-A | Topical composition and method for determining cooling capacity of composition | 未来医疗发展有限公司 | 2022-09-02 | — | — | CN | claimed |
| US-20220151918-A1 | TOPICAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ANAL FISSURES AND HEMORRHOIDS | FERRING B.V. (NL) | 2022-05-19 | — | — | US | claimed |
| EP-3220942-B1 | COMPOSITIONS COMPRISING LOW DOSE DESMOPRESSIN IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | SERENITY PHARMACEUTICALS LLC (US) | 2022-04-27 | — | — | EP | claimed |
| US-20220034911-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2022-02-03 | — | — | US | claimed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| WO-2025124483-A1 | ORAL DRUG DOSAGE FORM FOR TARGETED DRUG DELIVERY BASED ON TRACKING MARKER AND METHODS OF DESIGN AND USE THEREOF | Triastek, Inc. (CN) | 2025-06-19 | — | — | WO | disclosed |
| US-20250064781-A1 | METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING STRESS-RELATED DISORDER | UNIV YALE (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250041211-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATMENT OF PRESBYOPIA | Eye Hospital, Wenzhou Medical University (CN) | 2025-02-06 | — | — | US | disclosed |
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20220151918-A1 | TOPICAL PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ANAL FISSURES AND HEMORRHOIDS | FERRING B.V. (NL) | 2022-05-19 | — | — | US | disclosed |
| CN-114470207-A | Compositions and methods relating to treatment of pulmonary hypertension | 布里格姆及妇女医院股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-109431965-B | Pharmaceutical dosage forms and uses thereof | 南京三迭纪医药科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-114225119-A | Expandable balloon comprising a coating | 祥丰医疗私人有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-114173793-A | Composition, kit and use thereof | 泰瑞威公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114080220-A | Method for preparing gel-forming composition | 泰瑞威公司 | 2022-02-22 | — | — | CN | disclosed |
| US-20220034911-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165089-A1 | METHOD FOR TREATING MYOPIA WITH VINPOCETINE | MYOC, VAMP7, MYOF | ADRA1D 2899/4885ADRA1A 1692/4885ADRA1B 1935/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | ADRA1D 3567/4885ADRA1A 3325/4885ADRA1B 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.